ProMIS Neurosciences Announces Up To $122.7M Private Placement Financing; Proceeds Expected To Support Company Beyond 6 Month And 12 Month Data From The PMN310 Phase Ib Study In Alzheimer's Patients
ProMIS Neurosciences Announces Up To $122.7M Private Placement Financing; Proceeds Expected To Support Company Beyond 6 Month And 12 Month Data From The PMN310 Phase Ib Study In Alzheimer's Patients
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval
$3030万的融资款将预先支付，并有高达$9240万与认股权的行权相关联，其中某些认股权需股东批准。
Fundraise supports development of novel antibody PMN310 for Alzheimer's Disease patients
筹款支持新型抗体PMN310用于治疗阿尔茨海默病患者的开发。
Proceeds expected to support Company beyond 6 month and 12 month data from the PMN310 Phase Ib study in Alzheimer's patients
资金将用于PMN310阶段Ib研究中关于治疗阿尔茨海默病患者6个月和12个月数据之后的公司发展。
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN) ("ProMIS" or the "Company"), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has entered into a unit purchase agreement with certain new and existing institutional and accredited investors to issue and sell an aggregate of approximately $30.3 million of (a) common share units (the "Common Share Units"), with each Common Share Unit consisting of (i) one Common Share, without par value (a "Common Share"), (ii) one Tranche A Common Share purchase warrant to purchase one Common Share, (iii) one Tranche B Common Share purchase warrant to purchase one Common Share and (iv) one Tranche C Common Share purchase warrant to purchase one Common Share (each, a "Warrant", collectively, the "Warrants") and, for certain investors, (b) pre-funded units (the "Pre-Funded Units", and together with the Common Share Units, the "Units"), with each Pre-Funded Unit consisting of (i) one Pre-Funded Warrant to purchase one Common Share, (ii) one Tranche A Common Share purchase warrant to purchase one Common Share, (iii) one Tranche B Common Share purchase warrant to purchase one Common Share and (iv) one Tranche C Common Share purchase warrant to purchase one Common Share. The Common Share Units were sold at a price of $2.15 per Unit and the Pre-Funded Units were sold at a price of $2.14 per Unit through a private investment in public equity ("PIPE") financing.
加拿大安大略省和马萨诸塞州剑桥市，2024年7月26日（全球新闻社）- 生物技术公司ProMIS Neurosciences Inc.（纳斯达克上市公司：PMN）（“ProMIS”或“公司”）专注于生成和开发针对神经退行性疾病（如阿尔茨海默病（AD），肌萎缩性侧索硬化症（ALS）和多系统萎缩（MSA））中有毒错折蛋白的抗体治疗方法，今天宣布已与某些新投资方和现有机构投资者签订了一项单位购买协议，以发行约$3030万的（a）普通股单位（“普通股单位”），每个普通股单位包括（i）一股无面值普通股（“普通股”），（ii）一份Tranche A普通股购买认股权，可购买一股普通股，（iii）一份Tranche b普通股购买认股权，可购买一股普通股，以及（iv）一份Tranche C普通股购买认股权，可购买一股普通股（每份认股证书均称为“认股权证”，统称为“认股权”），以及（b）对于某些投资者，预先融资单位（“预先融资单位”） ，每个预先融资单位包括（i）一份预先融资认股权，可购买一股普通股，（ii）一份Tranche A普通股购买认股权，可购买一股普通股，（iii）一份Tranche b普通股购买认股权，可购买一股普通股，以及（iv）一份Tranche C普通股购买认股权，可购买一股普通股。普通股单位的发售价格为每单位$2.15，预先融资单位的发售价格为每单位$2.14（通过私募股权投资进行融资）。